Population Genetics Technologies to Open US Space, Aims for 2016 Launch of FDA-cleared HIV Dx | GenomeWeb

NEW YORK (GenomeWeb) – UK-based Population Genetics Technologies, which is developing infectious disease diagnostics, is opening up offices in Cleveland as it readies its HIV drug resistance and tropism test for launch in 2016 as a US Food and Drug Administration 510(k)-cleared and CE-marked product.

The HIV test is the first of several next-generation sequencing-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind, PGT CEO Alan Schafer told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.